Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_assertion type Assertion NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_head.
- NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_assertion description "[MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_provenance.
- NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_assertion evidence source_evidence_literature NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_provenance.
- NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_assertion SIO_000772 21118963 NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_provenance.
- NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_assertion wasDerivedFrom befree-20140225 NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_provenance.
- NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_assertion wasGeneratedBy ECO_0000203 NP861865.RACWlS3iNZT1ZwD0O64oPWl2sPo0h5SH3Ar6hUAzRBD70130_provenance.